Finast: Advanced 5α-Reductase Inhibitor for Effective Hair Regrowth
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $2.02 | $121.49 $121.49 (0%) | 🛒 Add to cart |
| 90 | $1.97 | $182.23 $177.71 (2%) | 🛒 Add to cart |
| 120 | $1.88 | $242.97 $225.90 (7%) | 🛒 Add to cart |
| 180 | $1.72 | $364.46 $309.24 (15%) | 🛒 Add to cart |
| 270 | $1.60
Best per pill | $546.69 $431.73 (21%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.61 | $78.31 (0%) | 🛒 Add to cart |
| 60 | $2.28 | $156.63 $136.55 (13%) | 🛒 Add to cart |
| 90 | $2.16 | $234.94 $194.78 (17%) | 🛒 Add to cart |
| 120 | $2.10 | $313.25 $252.01 (20%) | 🛒 Add to cart |
| 180 | $2.05 | $469.88 $368.47 (22%) | 🛒 Add to cart |
| 270 | $2.01
Best per pill | $704.82 $542.17 (23%) | 🛒 Add to cart |
Finast represents a breakthrough in the medical management of androgenetic alopecia, offering a scientifically validated approach to halting hair loss and promoting regrowth. As a selective inhibitor of Type II 5α-reductase, this prescription medication directly targets the hormonal pathway responsible for pattern hair loss in genetically predisposed individuals. Its well-documented efficacy profile and favorable safety record have established it as a first-line therapeutic option recommended by dermatologists worldwide. With consistent use, patients can expect measurable improvements in hair count, density, and overall scalp coverage.
Features
- Contains finasteride 1mg as the active pharmaceutical ingredient
- Selective inhibition of Type II 5α-reductase enzyme
- Reduces serum dihydrotestosterone (DHT) levels by approximately 70%
- Film-coated tablets for ease of administration
- Manufactured under cGMP standards
- Available in 30- and 90-day treatment packs
- Temperature-stable formulation
- Bioequivalent to brand-name formulations
Benefits
- Significantly slows progression of male pattern hair loss in 83% of users
- Promotes visible hair regrowth in vertex and anterior mid-scalp areas
- Prevents further miniaturization of hair follicles
- Improves hair thickness and density measurements
- Enhances patient self-esteem and quality of life indicators
- Provides cost-effective long-term management strategy
Common use
Finast is primarily indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men aged 18 years and older. It is prescribed for individuals experiencing progressive hair thinning in the vertex and anterior mid-scalp regions. The medication is most effective when initiated during early stages of hair loss, though benefits may be observed at various stages of androgenetic alopecia. Clinical studies demonstrate optimal outcomes when treatment begins before extensive miniaturization has occurred. Patients typically notice initial effects on hair shedding within 3-6 months, with maximal benefits apparent after 12-24 months of continuous therapy.
Dosage and direction
The recommended dosage is one 1mg tablet taken orally once daily, with or without food. Administration should occur at approximately the same time each day to maintain consistent plasma concentrations. Tablets should be swallowed whole with a full glass of water; they should not be crushed or chewed. Treatment response is dose-dependent and requires continuous therapy—discontinuation will lead to reversal of benefits within 12 months. For optimal absorption, avoid taking with high-fat meals if gastrointestinal upset occurs. Dosage adjustment is not typically required for elderly patients or those with mild to moderate renal impairment.
Precautions
Before initiating Finast therapy, patients should undergo thorough medical evaluation including assessment of prostate-specific antigen (PSA) levels if indicated. Regular monitoring of sexual function is recommended, as some patients may experience reversible adverse effects. Women who are or may become pregnant must not handle crushed or broken tablets due to risk of absorption through skin and potential fetal harm. Patients should be advised that treatment benefits may not be apparent for several months and require continued use. Those with liver impairment should use with caution and undergo periodic liver function tests. Annual follow-up evaluations are recommended to assess treatment efficacy and safety profile.
Contraindications
Finast is contraindicated in women who are pregnant or attempting to conceive due to risk of abnormalities in male fetal genital development. It is also contraindicated in pediatric patients and individuals with hypersensitivity to finasteride or any component of the formulation. Patients with existing severe hepatic impairment should avoid use unless potential benefits outweigh risks. Those with history of prostate cancer should not use Finast for androgenetic alopesis without urological consultation. Concurrent use with other 5α-reductase inhibitors is absolutely contraindicated.
Possible side effects
The most frequently reported adverse effects include decreased libido (1.8%), erectile dysfunction (1.3%), and ejaculation disorder (1.2%). These sexual side effects typically occur within the first year of treatment and often resolve with continued therapy or upon discontinuation. Less common effects include breast tenderness and enlargement (0.5%), rash (0.5%), and testicular pain (0.3%). Post-marketing surveillance has reported rare cases of persistent sexual dysfunction continuing after discontinuation, depression, and allergic reactions including lip swelling. Most adverse effects are mild to moderate in severity and reversible upon treatment cessation.
Drug interaction
Finast may interact with medications that inhibit CYP3A4 enzyme system, including ketoconazole, itraconazole, and ritonavir, potentially increasing finasteride exposure. Concurrent use with alpha-blockers may theoretically enhance hypotensive effects, though clinical significance is minimal at 1mg dosage. No clinically important interactions have been observed with warfarin, digoxin, propranolol, theophylline, or oral hypoglycemic agents. Patients taking saw palmetto or other herbal supplements with 5α-reductase inhibitory activity should exercise caution due to potential additive effects. Always inform healthcare providers of all prescription and non-prescription medications being taken.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume regular dosing schedule. Do not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining stable DHT suppression, but occasional missed doses are unlikely to significantly affect long-term treatment outcomes. Patients should maintain a regular dosing routine and consider using pill organizers or reminder systems if missed doses occur frequently.
Overdose
In clinical trials, single doses up to 400mg and multiple doses up to 80mg daily for three months have been administered without significant adverse effects. No specific antidote exists for finasteride overdose. In case of suspected overdose, symptomatic and supportive treatment should be initiated. Gastric lavage may be considered if ingestion occurred within previous hour. Since finasteride is highly protein-bound, dialysis is unlikely to be beneficial. Monitor vital signs and provide appropriate medical supervision. Report any overdose to poison control center for guidance.
Storage
Store Finast tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in original container with lid tightly closed to protect from moisture and light. Do not transfer tablets to other containers as this may affect stability. Keep out of reach of children and pets. Properly discard any expired or unused medication through medication take-back programs or according to local regulations. Do not flush medications down toilet or drain unless specifically instructed to do so.
Disclaimer
This information does not replace professional medical advice. Finast is available by prescription only and should be used under appropriate medical supervision. Individual results may vary based on multiple factors including duration of hair loss, age, and adherence to treatment regimen. Not all patients will respond to therapy, and some may experience side effects. Patients should discuss benefits and risks with their healthcare provider before initiating treatment. Regular follow-up is recommended to monitor efficacy and safety. This medication is not indicated for use in women or children.
Reviews
Clinical studies involving over 3,000 men demonstrated that 48% of patients showed improvement in hair growth after one year of treatment, compared to 7% with placebo. After five years of continuous therapy, 65% of men maintained or increased hair count from baseline. Patient satisfaction surveys indicate that 82% of long-term users would recommend treatment to others experiencing hair loss. Dermatological assessments confirm significant improvements in hair count (mean increase of 107 hairs in 1-inch diameter circle at vertex) and patient self-assessment scores. Real-world evidence supports maintained efficacy with continuous use up to 10 years with sustained safety profile.